Home » Newsletters » BioWorld Science

BioWorld Science

June 13, 2007

View Archived Issues

Recent patents disclose novel therapeutic agents for cardiovascular disorders

Novel estrone sulfatase inhibitor may be useful in ovarian cancer therapy

DDP-733 reduces esophageal reflux

Dimebon's benefits in Alzheimer's continue at 12 months

Nimotuzumab cleared for phase II trials in Canada for pediatric brain cancer and colorectal cancer

Cortex extends Ampakine license agreement with University of California, Irvine

Tanabe Seiyaku reports proof of concept for SGLT-2 inhibitor

Boston Life Sciences changes name to Alseres Pharmaceuticals

Novel gene therapy approach restores cone photoreceptor function in mouse models of cone dystrophies

New telomerase-targeting adenovirus therapy proves safe in preclinical studies

Innocoll files IND for surgical implant

Health Canada approves expanded indication for Plavix

Phase I results reported for dual Met/VEGFR-2 inhibitor XL-880

SBG enters phase III for diabetic ulcers

ARC-1779 completes phase I study

KB-2115 completes proof-of-concept phase II study in dyslipidemia

FDA requests additional data on alvimopan for postoperative ileus

Neopharm signs license for cintredekin besudotox in pulmonary fibrosis, asthma

Archemix signs aptamer agreements

CE Mark for OraQuick Advance Rapid HIV-1/2 Antibody Test

New phase I study of VB6-845 in advanced epithelial cancers

Preliminary clinical data on OGX-011 in prostate, non-small cell lung cancer presented

Apomab, a DR5 agonist antibody, well tolerated in initial clinical evaluation

Optaflu approved in E.U.

Pro-Pharmaceuticals begins filing for Davanat in coadministration with irinotecan

Favorable safety data reported for Stimuvax vaccine

AZD-0530 inhibits Src activity in human cancers

The anti-TGF-beta2 inhibitor AP-12009 in patients with solid tumors and tumors of the CNS

Japanese launch for Myozyme

New agents for treating neurological disorders disclosed in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...